Licensing and Collaboration Agreements - Additional Information (Details) - USD ($)		1 Months Ended				3 Months Ended	6 Months Ended	12 Months Ended			44 Months Ended
	Jan. 27, 2017	Sep. 30, 2021	May 31, 2021	May 31, 2017	Feb. 28, 2017	Jun. 30, 2021	Dec. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Sep. 30, 2020	Apr. 30, 2020	Mar. 31, 2017
Mars, Inc. | Research and Development
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
License fee								$ 0	$ 0	$ 0
Pfizer
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Reduction to research and development expense									1,500,000
Incyte Collaboration Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Percentage of sharing in global development cost											30.00%
Future profits and losses share percentage											40.00%
Upfront payment received					$ 45,000,000.0
Development milestone achieved													$ 12,000,000.0
Development milestone received				$ 12,000,000.0
Milestone payments the Company believed were due												$ 18,000,000.0
License revenue								57,000,000.0
Upfront consideration allocated to combined unit of accounting								45,000,000.0
Development milestone recognized								12,000,000.0
Net costs payable to (reimbursable by) Incyte								54,000	(8,000)	$ 200,000
Net amounts payable under collaboration agreement									$ 700,000
Incyte Collaboration Agreement | ASC 606
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration agreement transaction price							$ 57,000,000.0	57,000,000.0
Incyte Collaboration Agreement | Opt Out of Co-Funding Obligations
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Additional potential development, regulatory and commercialization milestones receivable							720,000,000.0	720,000,000.0
Incremental royalty percentage on annual net sales	3.00%
Maximum incremental royalty, percentage of previous development expenditure	120.00%
Incyte Collaboration Agreement | Incyte
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Percentage of sharing in global development cost											70.00%
Future profits and losses share percentage											60.00%
Incyte Settlement Agreement and Release
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payments receivable upon dispute settlement		$ 6,750,000
License revenue		$ 6,750,000
Antengene License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment received			$ 3,000,000.0
License revenue						$ 3,000,000.0	0
Antengene License Agreement | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Additional potential development, regulatory and sales milestones receivable							$ 252,000,000.0	252,000,000.0
Antengene License Agreement | ASC 606
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront consideration allocated to combined unit of accounting								$ 3,000,000.0